Early results of a new drug to treat asthma, lung problems, and chronic cough are encouraging, according to research published in the medical journal The Lancet.
Trials of the new drug ‘gefapixant’ (gefapixant) have been conducted in several countries, the volunteers included in the trial were aged from 18 to 59 years and all suffered from chronic cough.
According to British experts, after encouraging results in early trials of a new drug, wider experiments will be launched to test it, and thus the prospects of a new drug being introduced to the world after half a century have brightened.
The new drug has been hailed as a ‘game changer’ by experts and is expected to give the world another best treatment for chronic cough in 50 years. , that is, the complaint of cough is over.
It should be noted that chronic or chronic cough usually refers to a cough that lasts for 3 to 4 months, this cough usually occurs in people suffering from asthma and lung diseases.
Experts have expressed hope that a new drug to protect against chronic cough will soon be introduced in the world.
